Year All 2026 2025 2024 2023 2022 2021 2020 Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 November 4, 2026 Read More Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission November 4, 2026 Read More Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma November 4, 2026 Read More Lyell Immunopharma To Participate in November Investor Events November 2, 2026 Read More Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference September 14, 2026 Read More Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer September 10, 2026 Read More Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 August 6, 2026 Read More Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference June 25, 2026 Read More Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress June 12, 2026 Read More Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion June 8, 2026 Read More
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 November 4, 2026 Read More
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission November 4, 2026 Read More
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma November 4, 2026 Read More
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference September 14, 2026 Read More
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer September 10, 2026 Read More
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 August 6, 2026 Read More
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference June 25, 2026 Read More
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress June 12, 2026 Read More
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion June 8, 2026 Read More